<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671513</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-I-102</org_study_id>
    <nct_id>NCT02671513</nct_id>
  </id_info>
  <brief_title>A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients</brief_title>
  <official_title>A Tolerability and Pharmacokinetics Phase 1 Study of SHR6390 in Advanced Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this&#xD;
      study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in&#xD;
      Chinese advanced melanoma patients by using a &quot;3+3&quot; dose escalation.Preliminary efficacy will&#xD;
      be also investigated in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>3 weeks</time_frame>
    <description>The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one out of three subjects experience a dose-limiting toxicity (DLT) within the first 3 week of the first cycle of multiple dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390: Cmax</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390: Tmax</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390: t1/2</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of SHR6390: AUC</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experience adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 8 weeks, up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>SHR6390</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD</description>
    <arm_group_label>SHR6390</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed melanoma&#xD;
&#xD;
          -  Unresectable stage III or IV melanoma patient&#xD;
&#xD;
          -  companion with cell cycle pathway abnormal (e.g CDK4 amplify and/or CCND1 amplify&#xD;
             and/or CDKN2A loss)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status:0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate function of major organs, meaning the following criteria should be met within&#xD;
             14 days before randomization:&#xD;
&#xD;
        Hemoglobin &gt; 100g/L Neutrophils &gt; 2.0×10^9/L Platelets &gt; 100×10^9/L Total bilirubin &lt;&#xD;
        1.5×the upper limit of normal (ULN) ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver&#xD;
        metastases) Creatinine ≤ 1 ULN Left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
        QTcF(Fridericia correction) male≤450 ms, female≤470 ms&#xD;
&#xD;
          -  Good compliance of patient by physician's judgement&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received therapy of anti-tumor agent targeting at CDK4/6&#xD;
&#xD;
          -  Less than 3 weeks from the last cell-toxicity chemotherapy, less than 6 weeks from&#xD;
             last mitomycin or nitrosamine therapy&#xD;
&#xD;
          -  Less than 3 weeks from any other anti-tumor therapy (including targets therapy,&#xD;
             immunotherapy or other approved therapy)&#xD;
&#xD;
          -  Having joined in other clinical trials within 4 weeks&#xD;
&#xD;
          -  Uncontrolled/untreated brain metastasis (well-controlled/well-treated brain metastasis&#xD;
             by physician's judgement is allowed)&#xD;
&#xD;
          -  existing abnormal CTCAE≥grade 2 resulted from previous treatment&#xD;
&#xD;
          -  uncontrollable symptomatic pleural effusion or ascites or require clinical&#xD;
             intervention&#xD;
&#xD;
          -  require continous treatment by steroids&#xD;
&#xD;
          -  Factors influencing the usage of oral administration (e.g. unable to swallow, chronic&#xD;
             diarrhea and intestinal obstruction, etc.)&#xD;
&#xD;
          -  existing uncontrollable hypokalemia or hypomagnesemia&#xD;
&#xD;
          -  history of serious allergy events or known being allergy constitution&#xD;
&#xD;
          -  active HBV or HCV infection (HBV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)&#xD;
&#xD;
          -  History of immunodeficiency, acquired or congenital immunodeficiency, history of organ&#xD;
             transplantation&#xD;
&#xD;
          -  history of cardiac dysfunction, include(1)angina (2)clinical significant arrythmia or&#xD;
             require drug intervention (3)myocardial infarction (4)heart failure (5) other cardiac&#xD;
             dysfunction (judged by the physician); any cardiac or nephric abnormal ≥grade 2 found&#xD;
             in screening&#xD;
&#xD;
          -  Female patients who are pregnancy, lactation or women who are of childbearing&#xD;
             potential tested positive in baseline pregnancy test&#xD;
&#xD;
          -  childbearing female who refuse to accept any contraception practice&#xD;
&#xD;
          -  determined by the physician, any coexisting disease might lead to life threatening&#xD;
             complications or avoid the patients from accomplishing the treatment(e.g serious&#xD;
             hypertension, diabetes, thyroid dysfunction,etc.)&#xD;
&#xD;
          -  history of neuropathy or dysphrenia, including epilepsy and dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer hospital,Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Guo, M.D</last_name>
    <email>guoj307@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Liu, Ph.D</last_name>
    <email>liuy@shhrp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, M.D</last_name>
      <email>guoj307@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Cycline-Dependent Kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

